Fig. 4
Robust in vivo tumorigenicity in patient-derived xenograft (PDX). A. Diagram demonstrates the varying amounts of cells injected in mice using each of the three cell lines. B. Representative tumor volume (left) and tumor images (right) from GA0518 cells at injected three cell doses (105, 104, and 103 cells). C. Representative tumor volume (left) and tumor BLI images (right) from GA0804 cells at injected cell dosage (105 and 104 cells). D. Tumor volume (left) and representative tumor bioluminescence imaging (BLI) (right) from GA0825 cells at injected cell doses (106,105, 104, and 103 cells). Tumor growth was monitored by in vivo BLI weekly with intraperitoneal injection of 150 μg/g of D-Luciferin (PerkinElmer). Tumor weights of each group in GA0825 PDX was calculated by the end of the experiment (D, lower panel of right). E. Detailed summary of tumorigenicity of the three cell lines in mice